Stockreport

Madrigal: Rezdiffra Shift To F4c MASH Cirrhosis Continues With 2-Year Data [Seeking Alpha]

Madrigal Pharmaceuticals, Inc.  (MDGL) 
Last madrigal pharmaceuticals, inc. earnings: 2/26 06:50 am Check Earnings Report
US:NASDAQ Investor Relations: madrigalpharma.com
PDF MDGL is expanding Rezdiffra's reach, targeting F4 compensated MASH cirrhosis with the pivotal phase 3 MAESTRO-NASH-OUTCOMES trial; data is expected in 2027. Two-year [Read more]